Abstract
It is important to assess the stage of liver fibrosis in chronic hepatitis C to guide treatment decisions. Liver biopsy has limitations in staging fibrosis. Several blood tests, algorithms, and imaging tests have been studied as noninvasive markers to stage fibrosis in hepatitis C. In patients without suspicion for cirrhosis, 2 noninvasive methods can be used to predict presence of absence of significant liver fibrosis; however, liver biopsy remains the gold standard. It is imperative not to miss the diagnosis of cirrhosis, because this has further implications for screening of hepatocellular carcinoma and varices.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 849-861 |
| Number of pages | 13 |
| Journal | Infectious disease clinics of North America |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2012 |
| Externally published | Yes |
Keywords
- Hepatitis C
- Liver fibrosis
- Noninvasive staging
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Staging of Liver Disease. Which Option is Right for My Patient?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS